1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,200 | 0,220 | 12:15 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Boule Diagnostics AB: Boule Diagnostics Strengthens Long-Term Strategic Collaboration in India | 148 | GlobeNewswire (Europe) | Boule Diagnostics AB and Q-Line Biotech Limited have updated the licensing agreement between the two parties relating to diagnostic reagents, consumables and hematology analyzers for India market. The... ► Artikel lesen | |
| 31.08. | Boule Diagnostics AB: Bulletin from the Extraordinary General Meeting August 31, 2026 in Boule Diagnostics | 228 | GlobeNewswire (Europe) | The Extraordinary General Meeting (the "EGM") resolved to approve a loan from one of the company's major shareholders, AB Grenspecialisten, in accordance with the Board of Directors' proposal. Complete... ► Artikel lesen | |
| 17.07. | Boule Diagnostics AB: Boule Diagnostics Interim Report Q2 2026 | 187 | GlobeNewswire (Europe) | Quarter April-June 2026Net sales amounted to SEK 112.2 million (129.3), corresponding to a decrease of 13.3 percent. Organic sales growth amounted to -5.3 percent, currency effects amounted to -8.0... ► Artikel lesen | |
| 18.06. | Boule Diagnostics AB: Boule Diagnostics appoints new Chief Executive Officer | 691 | GlobeNewswire (Europe) | The Board of Directors at Boule Diagnostics has today appointed Johan Folkunger, Chief Executive Officer, effective June 22, 2026. Johan Folkunger succeeds Simonetta Tumbiolo, who has been serving... ► Artikel lesen | |
| 29.05. | Boule Diagnostics AB: Interim CEO at Boule Diagnostics | 203 | GlobeNewswire (Europe) | The board of directors at Boule Diagnostics has today appointed Simonetta Tumbiolo, currently Chief Commercial Officer Diagnostic, as Interim Chief Executive Officer, effective June 1 2026. As previously... ► Artikel lesen | |
| 13.05. | Boule Diagnostics AB: Bulletin from the Annual General Meeting May 13, 2026 in Boule Diagnostics | 338 | GlobeNewswire (Europe) | At the Annual General Meeting 2026 (the "AGM") it was resolved to adopt the balance sheets and profit and loss statements for the parent company and the group for the financial year 2025. The AGM resolved... ► Artikel lesen | |
| 28.04. | Boule Diagnostics AB: Boule Diagnostics Interim Report Q1 2026 | 204 | GlobeNewswire (Europe) | Stable start to 2026
Quarter January-March 2026} Net sales amounted to SEK 101.6 million (112.9), corresponding to a decrease of 10.0 percent. Organic sales growth amounted to 3.0 percent, currency... ► Artikel lesen | |
| 11.02. | Boule Diagnostics AB: Boule Diagnostics Year-end report 2025 | 421 | GlobeNewswire (Europe) | Improved operating cash flowQuarter October-December 2025Net sales amounted to SEK 120.2 million (143.2), corresponding to a decrease of 16.0 percent. Organic sales growth amounted to -11.7 percent... ► Artikel lesen | |
| BOULE DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 30.12.25 | Boule Diagnostics AB: Boule Diagnostics appoints Michael af Winklerfelt as new CFO | 388 | GlobeNewswire (Europe) | Boule Diagnostics AB appoints Michael af Winklerfelt as new CFO, effective February 2026. Michael af Winklerfelt brings extensive international experience from senior finance roles in pharmaceuticals... ► Artikel lesen | |
| 22.12.25 | Boule Diagnostics AB: Boule Diagnostics Selected as One of Three Providers in Nationwide Hematology Tender in Italy | 209 | GlobeNewswire (Europe) | Boule Diagnostics, together with its Italian distribution partner A. Menarini Diagnostics, is proud to announce its selection as one of only three providers in a nationwide tender for hematology solutions... ► Artikel lesen | |
| 05.12.25 | Boule Diagnostics AB: Boule Diagnostics Announces CEO Transition as Organization Prepares for Next Chapter | 244 | GlobeNewswire (Europe) | Boule Diagnostics today announced that Torben Nielsen, Chief Executive Officer, has decided to leave the company to pursue another professional opportunity. Under Torben's leadership, the company has... ► Artikel lesen | |
| 24.10.25 | Boule Diagnostics AB: Boule Diagnostics Interim Report Q3 2025 | 317 | GlobeNewswire (Europe) | Back to organic growth Quarter July-September 2025Net sales amounted to SEK 127.2 million (130.4), corresponding to a decrease of 2.4 percent. Organic sales growth amounted to 1.7 percent, currency... ► Artikel lesen | |
| 13.10.25 | Boule Diagnostics AB: Boule Diagnostics Announces CFO Departure for New Opportunity | 239 | GlobeNewswire (Europe) | Boule Diagnostics today announced that Holger Lembrér, Chief Financial Officer, will be leaving the company to pursue a new professional opportunity outside the organization.Torben Nielsen, CEO of Boule... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADAPTHEALTH | 6,065 | 0,00 % | Morning Market Movers: Ameresco, Inno Holdings, AdaptHealth, Ibotta See Big Swings | OTTAWA (dpa-AFX) - At 7:50 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 63,65 | 0,00 % | BMO Capital reiterates Outperform on BrightSpring Health stock | ||
| ALIGNMENT HEALTHCARE | 8,720 | +0,11 % | William Blair stuft Alignment Healthcare wegen Kostendruck und Rating-Herabstufung ab | ||
| FRESENIUS | 42,505 | +2,20 % | JEFFERIES stuft Fresenius SE auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Fresenius vor einem Treffen mit dem Chef Michael Sen auf "Buy" mit einem Kursziel von 55 Euro belassen. Die geschäftliche... ► Artikel lesen | |
| HEARTFLOW | 47,590 | 0,00 % | Biotech Stocks At 52-Week Highs - Vaxcyte +31% On Phase 3 Results, InfuSystem, Illumina +7%, Charles River Laboratories +7%, HeartFlow +5% | SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on October 5, 2026, driven by key catalysts such as encouraging clinical research data.Vaxcyte Inc. (PCVX)Vaxcyte is... ► Artikel lesen | |
| BILLIONTOONE | 95,41 | 0,00 % | BillionToOne, Inc.: BillionToOne's Tissue-Free Northstar Response Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds | MENLO PARK, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 37,630 | +2,48 % | EQS-Adhoc: Fresenius Medical Care AG: Wechsel im Vorstandsvorsitz - Shervin J. Korangy folgt auf Helen Giza | EQS-Ad-hoc: Fresenius Medical Care AG / Schlagwort(e): Personalentscheidungen / Vorstand
Fresenius Medical Care AG: Wechsel im Vorstandsvorsitz - Shervin J. Korangy folgt auf Helen... ► Artikel lesen | |
| PROGYNY | 27,820 | -0,04 % | Progyny expects 1.2 million new covered lives in 2027 | ||
| AVEANNA HEALTHCARE | 12,235 | 0,00 % | Aveanna Healthcare Holdings, Inc. - 8-K, Current Report | ||
| PRIVIA HEALTH GROUP | 20,180 | 0,00 % | Privia Health Group, Inc.: Privia Health to Report Third Quarter 2026 Results on Thursday, November 5 | ||
| GENEDX | 67,67 | 0,00 % | GeneDx: Starkes Wachstum trifft auf schwachen Forderungseinzug | ||
| LIFESTANCE HEALTH GROUP | 12,060 | 0,00 % | Transcript: LifeStance Health Gr Q2 2026 Earnings Conference Call | ||
| BETA BIONICS | 17,440 | 0,00 % | Beta Bionics, Inc.: Beta Bionics Announces Agreement Integrate the iLet Bionic Pancreas and mint with Senseonics' Eversense 365 | IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced a partnership... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 38,810 | +1,44 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| CONCENTRA GROUP | 36,670 | 0,00 % | Why Concentra's Quiet Healthcare Business Keeps Winning |
BOULE DIAGNOSTICS AB gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von +0,001 (+0,46 %) liegt der Kurs bei 0,210 Euro. Aus der Ausschüttung der letzten 12 Monate von insgesamt 0,00 Euro errechnet sich eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BOULE DIAGNOSTICS AB finden Sie auf Wallstreet Online.